...
首页> 外文期刊>Journal of Surgical Oncology >Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination
【24h】

Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination

机译:评价229例伴或不伴腹膜扩散的黏液性阑尾肿瘤患者的新分期分类和腹膜表面疾病严重度评分(PSDSS)

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Most classifications of mucinous appendiceal neoplasms (MAN) do not take into consideration the type of primary tumor or the burden of peritoneal disease.Materials and Methods: We conducted a retrospective evaluation of 229 patients with MAN. The severity of their disease was analyzed with the Peritoneal Surface Disease Severity Score (PSDSS) on a five-point scale that included: (1) the primary appendiceal tumor, (2) the type of peritoneal dissemination, and (3) the burden of disease. Overall survival was analyzed according to five tiers of estimated disease severity based on the above parameters.Results: There were 19, 67, 59, 43, and 41 patients with PSDSS 0, I, II, III, and IV, respectively. One hundred seventy-three patients underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Overall survival was 80.0 months in this group with 5-year survival of 100%, 79.2%, 23.3%, and 6.9% in patients with PSDSS I, II, III, and IV, respectively (P<0.001). On multivariate analysis, sex and PSDSS stage were identified as independent predictors of survival.Conclusions: The PSDSS appears to be an important prognostic indicator in patients with MANs with or without peritoneal dissemination and may improve selection of patients for appropriate therapy from the time of diagnosis.
机译:简介:大多数黏液性阑尾肿瘤的分类都没有考虑原发肿瘤的类型或腹膜疾病的负担。材料与方法:我们对229例MAN患者进行了回顾性评估。使用五分制的腹膜表面疾病严重度评分(PSDSS)分析其疾病的严重程度,包括:(1)原发性阑尾肿瘤;(2)腹膜扩散的类型;(3)负担疾病。根据上述参数,根据估计的疾病严重程度的五个等级对总生存期进行了分析。结果:分别有19、67、59、43和41例PSDSS为0,I,II,III和IV的患者。 173例患者接受了细胞减灭术(CRS)和高温腹膜内化疗(HIPEC)。该组的总生存期为80.0个月,PSDSS I,II,III和IV的患者的5年生存率分别为100%,79.2%,23.3%和6.9%(P <0.001)。在多因素分析中,性别和PSDSS分期被确定为生存的独立预测因素。结论:PSDSS似乎是MAN伴或不伴腹膜扩散的MAN患者的重要预后指标,从诊断之时起可能会改善患者选择合适的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号